What are the top 10 drugs with negotiated Medicare prices?

Editorial team Published on

The first 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act have negotiated prices (Maximum Fair Prices) that went into effect on January 1, 2026.

đź“‹ Top 10 Negotiated Drugs (2026)

  • Eliquis
    • Condition: Blood clots
    • Negotiated Price: $231 (56% off)
  • Enbrel
    • Condition: Rheumatoid arthritis and psoriasis
    • Negotiated Price: $2,355 (67% off)
  • Entresto
    • Condition: Heart failure
    • Negotiated Price: $295 (53% off)
  • Farxiga
    • Condition: Diabetes and heart failure
    • Negotiated Price: $178 (68% off)
  • NovoLog / Fiasp
    • Condition: Diabetes (insulin)
    • Negotiated Price: $119 (76% off)
  • Imbruvica
    • Condition: Blood cancers
    • Negotiated Price: $9,319 (38% off)
  • Januvia
    • Condition: Diabetes
    • Negotiated Price: $113 (79% off)
  • Jardiance
    • Condition: Diabetes and heart failure
    • Negotiated Price: $197 (66% off)
  • Stelara
    • Condition: Psoriasis and Crohn's disease
    • Negotiated Price: $4,695 (66% off)
  • Xarelto
    • Condition: Blood clots
    • Negotiated Price: $197 (62% off)

What are the 10 medications being negotiated?

The first 10 prescription medications selected by Medicare for price negotiations under the Inflation Reduction Act—with negotiated prices taking effect in 2026—are listed below:

The First 10 Negotiated Medications

  • Eliquis (apixaban) – Used for blood clot prevention and treatment.
  • Jardiance (empagliflozin) – Used for type 2 diabetes, heart failure, and chronic kidney disease.
  • Xarelto (rivaroxaban) – Used for blood clot prevention and treatment.
  • Januvia (sitagliptin) – Used for type 2 diabetes.
  • Farxiga (dapagliflozin) – Used for type 2 diabetes, heart failure, and chronic kidney disease.
  • Entresto (sacubitril/valsartan) – Used for heart failure.
  • Enbrel (etanercept) – Used for rheumatoid arthritis, psoriasis, and psoriatic arthritis.
  • Imbruvica (ibrutinib) – Used for blood cancers.
  • Stelara (ustekinumab) – Used for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
  • NovoLog / Fiasp (insulin aspart formulations) – Used for diabetes.

What are the names of the drugs on the 2026 Medicare Drug price negotiation list?

The first 10 drugs with Medicare-negotiated prices that take effect on January 1, 2026, include Eliquis, Jardiance, Xarelto, Januvia, Entresto, Stelara, Imbruvica, Farxiga, Enbrel, and NovoLog/Fiasp insulins.

You can review the full official background and details on the Centers for Medicare & Medicaid Services Fact Sheet.

2026 Negotiated Drugs and Uses

  • Eliquis (apixaban): Blood thinner to prevent blood clots and strokes
  • Jardiance (empagliflozin): Type 2 diabetes and heart failure
  • Xarelto (rivaroxaban): Blood thinner for stroke and blood clot prevention
  • Januvia (sitagliptin): Type 2 diabetes
  • Entresto (sacubitril/valsartan): Heart failure
  • Stelara (ustekinumab): Psoriasis and Crohn's disease
  • Imbruvica (ibrutinib): Blood cancers like leukemia and lymphoma
  • Farxiga (dapagliflozin): Type 2 diabetes, heart failure, and chronic kidney disease
  • Enbrel (etanercept): Rheumatoid arthritis
  • NovoLog / Fiasp (various insulin products): Diabetes care

Which drugs are currently on the Medicare price negotiation list?

Medicare has negotiated lower prices for key high-cost prescription drugs under the CMS Medicare Drug Price Negotiation Program established by the Inflation Reduction Act.

Negotiated Drugs Effective January 1, 2026 (Round 1 - Part D)

  • Eliquis (blood clots)
  • Jardiance (diabetes, heart failure)
  • Xarelto (blood clots)
  • Januvia (diabetes)
  • Farxiga (diabetes, heart failure)
  • Entresto (heart failure)
  • Enbrel (rheumatoid arthritis, psoriasis)
  • Imbruvica (blood cancers)
  • Stelara (psoriasis, Crohn's disease)
  • NovoLog / Fiasp (insulin products)

Selected Drugs Effective January 1, 2027 (Round 2 - Part D)

  • Includes 15 additional high-spend medications such as Ozempic, Xtandi, Pomalyst, Ibrance, Ofev, and Trelegy Ellipta.

Selected Drugs Effective January 1, 2028 (Round 3 - Parts B & D)

  • Includes 15 new selections (incorporating Part B medications for the first time) such as Biktarvy, Trulicity, Cosentyx, Orencia, Botox, and Xolair, alongside the renegotiation of Tradjenta.

What are the 10 most expensive Medicare drugs?

The 10 costliest prescription drugs for Medicare—based on total overall program spending and targeted under the initial federal price negotiation program—include widely used treatments for blood clots, diabetes, and cancer.

Top 10 High-Spend Medicare Part D Drugs

The first 10 medications selected for maximum price adjustments under the Centers for Medicare & Medicaid Services framework represent some of the highest total expenditures for the program:

  • Eliquis (apixaban): Anticoagulant used to prevent and treat blood clots.
  • Jardiance (empagliflozin): Treats type 2 diabetes and heart failure.
  • Xarelto (rivaroxaban): Blood thinner used for stroke and blood clot prevention.
  • Farxiga (dapagliflozin): Manages type 2 diabetes, heart failure, and chronic kidney disease.
  • Januvia (sitagliptin): Oral medication to control blood sugar in type 2 diabetes.
  • Entresto (sacubitril/valsartan): Combination drug prescribed for heart failure.
  • Stelara (ustekinumab): Biologic therapy for Crohn’s disease, psoriasis, and plaque psoriasis.
  • Enbrel (etanercept): Treats rheumatoid arthritis and other autoimmune conditions.
  • NovoLog / Fiasp (insulin aspart): Rapid-acting insulins for blood glucose control.
  • Imbruvica (ibrutinib): Targeted cancer therapy for specific blood cancers like leukemias.

Medicare Drug Price Negotiation 2024 - Top 10 Drug Price Negotiations Explained | NASE.org

9 related questions found

What 5 medications do doctors say not to take?

Doctors often recommend getting rid of or avoiding specific over-the-counter and routine medications because new evidence shows they are ineffective or carry unnecessary risks.

Based on recent medical guidance highlighted by physicians (such as recent recommendations featured by the Washington Post), here are 5 medications doctors frequently advise reconsidering or dropping from your medicine cabinet:

1. Oral Phenylephrine

  • What it is: A common oral decongestant found in many over-the-counter cold, flu, and sinus products (like certain versions of Sudafed PE or DayQuil).
  • Why doctors say to avoid it: The FDA determined that oral phenylephrine is completely ineffective as a nasal decongestant.
  • What to do instead: If you need a real oral decongestant, ask a pharmacist for pseudoephedrine from behind the pharmacy counter, which actually works.

2. Diphenhydramine (Benadryl)

  • What it is: A first-generation antihistamine widely used for allergies and sleep.
  • Why doctors say to avoid it: Especially for adults over 65, it causes severe side effects like heavy daytime grogginess, confusion, high risk of falls, and trouble urinating. Chronic use has also been linked to cognitive decline.
  • What to do instead: Switch to newer, safer second-generation antihistamines like loratadine (Claritin) or cetirizine (Zyrtec).

3. Daily Low-Dose Aspirin (for Primary Prevention)

  • What it is: Taking a daily aspirin to prevent a first heart attack or stroke.
  • Why doctors say to avoid it: Updated guidelines advise against starting daily aspirin if you have never had a cardiovascular event, because the risk of dangerous stomach bleeding often outweighs the preventative benefits. (Note: If you already take it under strict doctor's orders for an existing heart condition, do not stop without talking to them).
  • What to do instead: Talk to your physician to re-evaluate your personal risk factors and see if a daily aspirin is still appropriate for you.

4. Docusate Sodium (Colace)

  • What it is: A widely sold over-the-counter stool softener.
  • Why doctors say to avoid it: Robust clinical trials have shown it is largely ineffective as a standalone treatment for constipation.
  • What to do instead: Increase your intake of water and try a natural fiber supplement or osmotic laxative if recommended by your care team.

5. Old Codeine Cough Syrup

  • What it is: Prescription opioid-based cough medicine kept in home medicine cabinets.
  • Why doctors say to avoid it: Studies show codeine cough syrup performs no better than a placebo for suppressing coughs, but carries serious risks of dependence, accidental misuse, and dangerous slowed breathing.
  • What to do instead: Safely dispose of leftover prescription narcotics through a community drug take-back program.

What drugs will become generic in 2026?

Several major brand-name drugs are losing patent exclusivity or seeing their first generic approvals and market launches in 2026.

Key Medications Slated for Generic or Biosimilar Availability in 2026

  • Januvia (sitagliptin) and Janumet (sitagliptin/metformin): Merck's blockbuster diabetes medications face generic competition following patent and litigation settlements.
  • Farxiga (dapagliflozin): The FDA approved the First Generic Drug Approvals for dapagliflozin tablets in April 2026.
  • Pomalyst (pomalidomide): Bristol Myers Squibb's multiple myeloma drug faces expected generic market entries in 2026.
  • Xtandi (enzalutamide): Generic enzalutamide received final FDA approval in early 2026 for commercial rollout.
  • Xolair (omalizumab): Biosimilar competition for Roche's biologic asthma and allergy treatment is expected to launch in the second half of 2026.
  • Brilinta (ticagrelor): Slated for generic market transition during 2026.
  • Entresto (sacubitril/valsartan): Novartis faces patent expirations for this crucial heart-failure medication.

(Note: For high-demand medications like Ozempic/Wegovy [semaglutide] or Mounjaro/Zepbound [tirzepatide], true FDA-approved retail generics are delayed due to complex device and secondary patent layering well into the future, meaning current low-cost alternatives are typically unregulated compounded peptides rather than official generics.) You can review a broader tracking list via Drugs.com Generic Approvals.

What is the number one selling prescription drug?

The top-selling prescription medication globally is Keytruda (pembrolizumab), a cancer immunotherapy made by Merck & Co., which brought in roughly $31.68 billion in global revenue.

Top-Selling Drug Details

  • Keytruda (pembrolizumab): A biologic therapy used to treat various cancers like melanoma and non-small cell lung cancer.
  • Close Competitors: Eli Lilly's tirzepatide—marketed as Mounjaro for type 2 diabetes and Zepbound for obesity—has surged rapidly as a top global seller, alongside Novo Nordisk's diabetes and weight-loss drugs Ozempic and Wegovy.
  • Past Leader: AbbVie's autoimmune drug Humira (adalimumab) held the top spot for years until patent expirations and biosimilar competition reduced its sales.

What is the #1 most prescribed drug?

Atorvastatin (commonly known by the brand name Lipitor) is the number one most prescribed drug in the United States, with over 115 million prescriptions filled annually.

What Atorvastatin Does

  • High Cholesterol: It belongs to a class of medications called statins.
  • Mechanism: It blocks a liver enzyme that makes cholesterol to help lower bad cholesterol and fats in the blood.
  • Cardiovascular Health: Doctors prescribe it with diet and exercise to lower the risk of stroke, heart attack, and chest pain.

Other Top Prescribed Medications

  • Levothyroxine sodium: A synthetic thyroid hormone used to treat hypothyroidism.
  • Metformin hcl: A medication used to manage blood sugar levels in type 2 diabetes.
  • Amlodipine besylate: A calcium channel blocker used to treat high blood pressure and chest pain.

Did Trump lower Ozempic prices?

President Donald Trump announced agreements with Ozempic maker Novo Nordisk to lower the cost of the medication to between $199 and $350 per month through the TrumpRx program.

The Trump administration Agreement and Pricing

  • Direct-to-Consumer Pricing: Under the "most-favored-nation" pricing agreements announced by the White House, Ozempic prices are listed at $350 per month (with promotional or lower tiers around $199 depending on the exact program or dosage) through TrumpRx, down from standard retail list prices of roughly $1,000.
  • Medicare and Medicaid: The administration stated that eligible patients on Medicare and Medicaid would see reduced pricing, with projected costs around $245 per month and copays as low as $50 for certain high-risk patients.

Context and Expert Reception

  • Manufacturer Role: Novo Nordisk and Eli Lilly agreed to the pricing framework in exchange for specific terms, such as tariff exemptions and commitments to expand U.S. manufacturing capacity.
  • Real-World Impact: According to health policy and drug-pricing experts cited by sources like PBS NewsHour, the actual savings can be complex. Official list prices do not always reflect what insured patients or government programs already pay after standard rebates, discounts, and prior coverage rules.